Thrivelab — a national telehealth provider specializing in evidence-based bioidentical hormone replacement therapy — has further solidified its focus on women’s testosterone therapy by welcoming fitness expert Chris Powell as its Chief Transformation Officer. This move aims to expand education and access to a historically underserved area of female health.
While dozens of testosterone formulations are approved for men in the United States, no FDA-approved version exists for women, leaving many to suffer from fatigue, low libido, brain fog, mood swings, and muscle loss without adequate treatment options. Thrivelab addresses this gap by offering compounded bioidentical testosterone alongside broader hormone, primary care, nutrition, and coaching services specifically tailored to women in perimenopause, menopause, and beyond, with prescriptions filled through licensed compounding pharmacies and insurance coverage accepted.
Image Credit: Thrivelab
Why This Trend Is Growing
- Women-centric Hormone Telehealth
- A rise in virtual clinics focused on female hormone care is creating new models for scalable, personalized management of perimenopause and menopause symptoms.
- Compounded Bioidentical Therapies
- The reliance on pharmacist-compounded testosterone formulations for women highlights an evolving pharmaceutical niche outside traditional FDA-approved product pathways.
- Fitness-led Clinical Leadership
- Integrating high-profile fitness and lifestyle expertise into medical leadership is reshaping patient engagement and adherence in chronic women’s health treatments.
Industries Being Reshaped
- Telehealth Services
- Remote primary care and specialty telemedicine platforms are enabling broader access and continuity for women seeking hormone-related consultations and follow-up.
- Compounding Pharmacy
- Licensed compounding pharmacies are positioned as critical supply-chain partners for customized hormone formulations that address dosing and delivery gaps for female patients.
- Women’s Health Technology
- Digital health tools tailored to perimenopause and menopause monitoring are generating data-driven opportunities for symptom tracking and personalized treatment optimization.
